Rating Change
BMO Capital reiterated its Market Perform rating on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on October 12, 2026.
reiterateNASDAQ:NBIX
BMO Capital Reiterates Market Perform Rating on Neurocrine Biosciences, Inc. (NBIX)
BMO Capital reiterated its Market Perform rating on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on October 12, 2026.
At publication ·
What changed
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) · reiterate
- Firm
- BMO Capital
- Rating
- Market Perform to Market Perform
- Price at event
- $141.37
- Market capitalization
- $15.4B
At a glance
Key takeaways
- BMO Capital maintained a Market Perform rating on Neurocrine Biosciences (NBIX) on October 12, 2026, with the stock trading at $141.37 and a market cap of $15.4B.
Market Context
Neurocrine Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $141.37 with a market capitalization of $15.4B. The stock has gained 3.0% over the past 52 weeks.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurocrine Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Neurocrine Biosciences, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | BMO Capital | Market Perform | N/A |
| Sep 29, 2026 | UBS | Buy | N/A |
| Sep 11, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Sep 08, 2026 | RBC Capital | Outperform | N/A |
| Sep 03, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NBIX Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for NBIX?
A rating of Market Perform from BMO Capital reflects the analyst's outlook on Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NBIX forecast page.